	US 12,435,055 B2
	3-methylideneoxan-4-one compounds and substituted derivates thereof as inhibitors of telomerase
Karl A. Scheidt, Evanston, IL (US); and Rick C. Betori, Gurnee, IL (US)
Assigned to Northwestern University, Evanston, IL (US)
Filed by Northwestern University, Evanston, IL (US)
Filed on Oct. 13, 2022, as Appl. No. 17/965,352.
Application 17/965,352 is a continuation of application No. 16/986,718, filed on Aug. 6, 2020, granted, now 11,518,750.
Claims priority of provisional application 62/883,588, filed on Aug. 6, 2019.
Prior Publication US 2023/0115088 A1, Apr. 13, 2023
Int. Cl. C07D 309/32 (2006.01); A61K 31/351 (2006.01); A61K 31/4192 (2006.01); A61K 31/4427 (2006.01); A61K 31/496 (2006.01); A61K 31/5377 (2006.01); C07D 405/06 (2006.01)

CPC C07D 309/32 (2013.01) [A61K 31/351 (2013.01); A61K 31/4192 (2013.01); A61K 31/4427 (2013.01); A61K 31/496 (2013.01); A61K 31/5377 (2013.01); C07D 405/06 (2013.01)]

4 Claims

1. A method of treating cancer associated with telomerase activity in a subject in need of treatment, the method comprising administering to the subject a composition comprising an effective amount of a compound having a formula selected from the group consisting of:

or a salt or hydrate thereof, and a pharmaceutically acceptable carrier.